Submit to Special Issue Submit Abstract to Special Issue Review for Medicina Edit a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers
Planned Papers

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 10844

Share This Special Issue

Special Issue Editors

Prof. Dr. Valentin Titus Grigorean

E-Mail Website
Guest Editor

1. Department of General Surgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
2. Department of General Surgery, "Bagdasar-Arseni" Emergency Clinical Hospital, Bucharest, Romania
Interests: oncologic surgery; trauma surgery; hepato-pancreatobiliary surgery

Dr. Daniel Alin Cristian

E-Mail Website
Guest Editor

1. Department of General Surgery, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania
2. Department of General Surgery, “Colţea” Clinical Hospital, Bucharest, Romania
Interests: oncologic surgery; hepato-pancreatobiliary surgery

Special Issue Information

Dear Colleagues,

Cancer is the leading cause of death worldwide, accounting for more than 10 million deaths each year and even a larger number of patients that are diagnosed with this disease and have to undergo various procedures. All of this has happened following the increased number of risk factors that have become present in our lives in recent decades, such as tobacco, obesity and various unhealthy food diets, alcohol, viral infections, exposure to certain chemicals or radiations, etc.

Our goal as medical practitioners or as scientists is to obtain the best outcome for our patients, from prophylactic procedures to a correct diagnosis, a specific multimodal treatment, and a rigorous follow-up. All these have significantly improved in recent years because of a better understanding of the genetic and molecular mechanisms of cancer development, the emergence of new technologies in cancer detection or surgical techniques, and also breakthroughs in oncological therapies.

The aim of this Special Issue is to obtain new insights into advances in the cancer multimodal approach; therefore, we encourage authors to submit their systematic reviews, meta-analyses, clinical outcome studies or new surgical techniques and oncological therapies regarding this subject.

Prof. Dr. Valentin Titus Grigorean
Dr. Daniel Alin Cristian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cancer
mechanism
surgery
multimodal
advances

Published Papers (12 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

Open AccessEditorial

Cancer—Yesterday, Today, Tomorrow

Valentin Titus Grigorean

and

Daniel Alin Cristian

Medicina 2023, 59(1), 98; https://doi.org/10.3390/medicina59010098 - 31 Dec 2022

Viewed by 733

Abstract

The COVID-19 pandemic has brought infectious and contagious diseases back to the forefront of medical concerns worldwide [...] Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

Research

Jump to: Editorial, Review, Other

Open AccessArticle

Parathyroid Cancer—A Rare Finding during Parathyroidectomy in High Volume Surgery Centre

and

Medicina 2023, 59(3), 448; https://doi.org/10.3390/medicina59030448 - 23 Feb 2023

Cited by 1 | Viewed by 581

Abstract

Background and Objectives: Parathyroid cancer is a very rare endocrine tumor, especially in patients with secondary hyperparathyroidism due to end stage renal disease failure. This pathology is difficult to diagnose preoperatively because it has nonspecific clinical manifestations and paraclinical aspects. Our study of the literature identified 34 reported cases of parathyroid carcinoma over the last 40 years in patients undergoing dialysis. We present our experience as illustrative of the features of clinical presentation and histopathological findings of parathyroid carcinoma and assess its management considering the recent relevant literature. Materials and Methods: From January 2012 to November 2022, 650 patients with secondary hyperparathyroidism undergoing dialysis were treated at our academic Department of General Surgery and only two cases of parathyroid carcinoma were diagnosed on histopathological examination. Results: All patients presented with symptomatic hypercalcemia, with no clinical or imaging suspicion of malignant disease and were surgically treated by total parathyroidectomy. Histopathological examination revealed morphologic aspects of parathyroid carcinoma in two cases and immunostaining of Ki-67 was performed for diagnostic confirmation. Postoperative follow-up showed no signs of recurrence and no oncological adjuvant treatment or surgical reinterventions were needed. Conclusions: Parathyroid neoplasia is a particularly rare disease, that remains a challenge when it comes to diagnosis and proper management. Surgical approach is the only valid treatment to remove the malignant tissue and thus improve the patient’s prognosis. Medical and oncologic treatment may be beneficial to control hypercalcemia in case of tumor recurrence. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessArticle

Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells

Mahin Taheri Moghadam

Seyed Mohammad Jafar Haeri

and

Katsuhiko Suzuki

Medicina 2023, 59(2), 286; https://doi.org/10.3390/medicina59020286 - 01 Feb 2023

Viewed by 828

Abstract

Background and Objectives: Combination therapy improves the effect of chemotherapy on tumor cells. Magnolol, used in treating gastrointestinal disorders, has been shown to have anti-cancer properties. We investigated the synergistic effect of cisplatin and magnolol on the viability and maintenance of MKN-45 gastric cancer cells. Materials and Methods: The toxicity of magnolol and/or cisplatin was determined using the MTT technique. The trypan blue method was used to test magnolol and/or cisplatin’s effect on MKN-45 cell growth. Crystal violet staining was used to assess the treated cells’ tendency for colony formation. The expression of genes linked to apoptosis, cell cycle arrest, and cell migration was examined using the qPCR method. Results: According to MTT data, using magnolol and/or cisplatin significantly reduced cell viability. The ability of the treated cells to proliferate and form colonies was also reduced considerably. Magnolol and/or cisplatin treatment resulted in a considerable elevation in Bax expression. However, the level of Bcl2 expression was dramatically reduced. p21 and p53 expression levels were significantly increased in the treated cells, while MMP-9 expression was significantly reduced. Conclusions: These findings show that magnolol has a remarkable anti-tumor effect on MKN-45 cells. In combination with cisplatin, magnolol may be utilized to overcome cisplatin resistance in gastric cancer cells. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessArticle

Validation of a New Prognostic Score in Patients with Ovarian Adenocarcinoma

Oana Gabriela Trifanescu

Radu Iulian Mitrica

Laurentia Nicoleta Gales

Serban Andrei Marinescu

Natalia Motas

Raluca Alexandra Trifanescu

Laura Rebegea

Mirela Gherghe

Dragos Eugen Georgescu

Georgia Luiza Serbanescu

Haj Hamoud Bashar

Serban Dragosloveanu

Daniel Alin Cristian

and

Rodica Maricela Anghel

Medicina 2023, 59(2), 229; https://doi.org/10.3390/medicina59020229 - 26 Jan 2023

Viewed by 758

Abstract

Background and Objectives: This study aimed to assess the impact of clinical prognostic factors and propose a prognostic score that aids the clinician’s decision in estimating the risk for patients in clinical practice. Materials and Methods: The study included 195 patients diagnosed with ovarian adenocarcinoma. The therapeutic strategy involved multidisciplinary decisions: surgery followed by adjuvant chemotherapy (80%), neoadjuvant chemotherapy followed by surgery (16.4%), and only chemotherapy in selected cases (3.6%). Results: After a median follow-up of 68 months, in terms of progression-free survival (PFS) and overall survival (OS), Eastern Cooperative Oncology Group (ECOG) performance status of 1 and 2 vs. 0 (hazard ratio—HR = 2.71, 95% confidence interval—CI, 1.96–3.73, p < 0.001 for PFS and HR = 3.19, 95%CI, 2.20–4.64, p < 0.001 for OS), menopausal vs. premenopausal status (HR = 2.02, 95%CI, 1.35–3,0 p < 0.001 and HR = 2.25, 95%CI = 1.41–3.59, p < 0.001), ascites (HR = 1.95, 95%CI 1.35–2.80, p = 0.03, HR = 2.31, 95%CI = 1.52–3.5, p < 0.007), residual disease (HR = 5.12, 95%CI 3.43–7.65, p < 0.0001 and HR = 4.07, 95%CI = 2.59–6.39, p < 0.0001), and thrombocytosis (HR = 2.48 95%CI = 1.72–3.58, p < 0.0001, HR = 3.33, 95%CI = 2.16–5.13, p < 0.0001) were associated with a poor prognosis. An original prognostic score including these characteristics was validated using receiver operating characteristic (ROC) curves (area under the curve—AUC = 0.799 for PFS and AUC = 0.726 for OS, p < 0.001). The median PFS for patients with none, one, two, three, or four (or more) prognostic factors was not reached, 70, 36, 20, and 12 months, respectively. The corresponding median overall survival (OS) was not reached, 108, 77, 60, and 34 months, respectively. Conclusions: Several negative prognostic factors were identified: ECOG performance status ≥ 1, the presence of ascites and residual disease after surgery, thrombocytosis, and menopausal status. These led to the development of an original prognostic score that can be helpful in clinical practice. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessArticle

Cancer-Oriented Comprehensive Nursing Services in Republic of Korea: Lessons from an Oncologist’s Perspective

and

Medicina 2023, 59(1), 144; https://doi.org/10.3390/medicina59010144 - 11 Jan 2023

Viewed by 837

Abstract

Background and objectives: As is well known, cancer patients require extensive medical attention as they undergo surgery, chemotherapy, radiotherapy, and supportive care. The importance of high-quality cancer-directed nursing, combined with precision medicine, to maximize their survival outcomes and help them achieve a better quality of life cannot be overemphasized. In this context, we offered a new cancer-oriented comprehensive nursing system to our inpatients and reviewed its clinical outcomes in comparison with those from the preexisting general cancer ward. Materials and Methods: From March 2019 to February 2020, a total of 102 cancer patients and 42 nurses were enrolled in this pilot study. We aimed to analyze their performance in three main categories: structure, process, and patient/nurse outcomes. Results: First, structural (nurse staffing and environment) upgrades were installed in the cancer-oriented comprehensive nursing ward, including an improved nurse-patient ratio (1:8 in the comprehensive ward as compared with 1:14 in the general ward), wider space between beds (1.5 m versus 1.0 m), fully automatic beds with fall prevention sensors, etc. Second, the nursing process was improved (missed care 0.1 event/month vs. 1.3 event/month). Third, both patient and nurse outcomes showed preferable results in the comprehensive ward. The patient satisfaction level was higher in the comprehensive nursing ward than in the general ward (willing to revisit: 91.7% and 78.4%, respectively; willing to recommend to others: 95.0% and 76.8%, respectively). Pressure ulcers, as a patient safety indicator, were also decreased (0.3 events/month vs. 0.8 events/month). However, the fall incidence was similar in both groups (1.6 events/month vs. 1.5 events/month). In terms of nurse outcomes, turnover intention was stabilized and nurses’ job satisfaction in the comprehensive ward was superior to that of their counterparts. Conclusions: Our study was a pilot study to demonstrate that cancer patient-oriented comprehensive nursing services can be helpful in improving the quality of cancer treatment and nurses’ job satisfaction. Continued interest in and efforts to improve nursing care delivery are also crucial in achieving and maintaining the best possible cancer patient care. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

Open AccessReview

CD34—Structure, Functions and Relationship with Cancer Stem Cells

and

Medicina 2023, 59(5), 938; https://doi.org/10.3390/medicina59050938 - 12 May 2023

Viewed by 552

Abstract

The CD34 protein was identified almost four decades ago as a biomarker for hematopoietic stem cell progenitors. CD34 expression of these stem cells has been exploited for therapeutic purposes in various hematological disorders. In the last few decades, studies have revealed the presence of CD34 expression on other types of cells with non-hematopoietic origins, such as interstitial cells, endothelial cells, fibrocytes, and muscle satellite cells. Furthermore, CD34 expression may also be found on a variety of cancer stem cells. Nowadays, the molecular functions of this protein have been involved in a variety of cellular functions, such as enhancing proliferation and blocking cell differentiation, enhanced lymphocyte adhesion, and cell morphogenesis. Although a complete understanding of this transmembrane protein, including its developmental origins, its stem cell connections, and other functions, is yet to be achieved. In this paper, we aimed to carry out a systematic analysis of the structure, functions, and relationship with cancer stem cells of CD34 based on the literature overview. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessReview

Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer

Melanie Schubert

Dirk Olaf Bauerschlag

Mustafa Zelal Muallem

Nicolai Maass

and

Ibrahim Alkatout

Medicina 2023, 59(5), 925; https://doi.org/10.3390/medicina59050925 - 11 May 2023

Viewed by 593

Abstract

Cervical cancer is still the fourth most common cancer in women throughout the world; an estimated 604,000 new cases were observed in 2020. Better knowledge of its pathogenesis, gained in recent years, has introduced new preventive and diagnostic approaches. Knowledge of its pathogenesis has made it possible to provide individualized surgical and drug treatment. In industrialized countries, cervical cancer has become a less frequent tumor entity due to the accessibility of the human papilloma virus vaccination, systematic preventive programs/early detection programs, health care infrastructure and the availability of effective therapy options. Nevertheless, globally, neither mortality nor morbidity has been significantly reduced over the past 10 years, and therapy approaches differ widely. The aim of this review is to address recent advances in the prevention, diagnostic investigation and treatment of cervical cancer globally, focusing on advances in Germany, with a view toward providing an updated overview for clinicians. The following aspects are addressed in detail: (a) the prevalence and causes of cervical cancer, (b) diagnostic tools using imaging techniques, cytology and pathology, (c) pathomechanisms and clinical symptoms of cervical cancer and (d) different treatment approaches (pharmacological, surgical and others) and their impact on outcomes. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessReview

Colorectal Cancer—The “Parent” of Low Bowel Obstruction

Valentin Titus Grigorean

Anwar Erchid

Ionuţ Simion Coman

and

Mircea Liţescu

Medicina 2023, 59(5), 875; https://doi.org/10.3390/medicina59050875 - 02 May 2023

Viewed by 663

Abstract

Introduction: Despite the improvement of early diagnosis methods for multiple pathological entities belonging to the digestive tract, bowel obstruction determined by multiple etiologies represents an important percentage of surgical emergencies. General data: Although sometimes obstructive episodes are possible in the early stages of colorectal cancer, the most commonly installed intestinal obstruction has the significance of an advanced evolutionary stage of neoplastic disease. Development of Obstructive Mechanism: The spontaneous evolution of colorectal cancer is always burdened by complications. The most common complication is low bowel obstruction, found in approximately 20% of the cases of colorectal cancer, and it can occur either relatively abruptly, or is preceded by initially discrete premonitory symptoms, non-specific (until advanced evolutionary stages) and generally neglected or incorrectly interpreted. Success in the complex treatment of a low neoplastic obstruction is conditioned by a complete diagnosis, adequate pre-operative preparation, a surgical act adapted to the case (in one, two or three successive stages), and dynamic postoperative care. The moment of surgery should be chosen with great care and is the result of the experience of the anesthetic-surgical team. The operative act must be adapted to the case and has as its main objective the resolution of intestinal obstruction and only in a secondary way the resolution of the generating disease. Conclusions: The therapeutic measures adopted (medical-surgical) must have a dynamic character in accordance with the particular situation of the patient. Except for certain or probably benign etiologies, the possibility of colorectal neoplasia should always be considered, in low obstructions, regardless of the patient’s age. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessReview

Mass Spectrometry Contribution to Pediatric Cancers Research

Marco Agostini

Pietro Traldi

and

Mahmoud Hamdan

Medicina 2023, 59(3), 612; https://doi.org/10.3390/medicina59030612 - 20 Mar 2023

Viewed by 638

Abstract

For over four decades, mass spectrometry-based methods have provided a wealth of information relevant to various challenges in the field of cancers research. These challenges included identification and validation of novel biomarkers for various diseases, in particular for various forms of cancer. These biomarkers serve various objectives including monitoring patient response to the various forms of therapy, differentiating subgroups of the same type of cancer, and providing proteomic data to complement datasets generated by genomic, epigenetic, and transcriptomic methods. The same proteomic data can be used to provide prognostic information and could guide scientists and medics to new and innovative targeted therapies The past decade has seen a rapid emergence of epigenetics as a major contributor to carcinogenesis. This development has given a fresh momentum to MS-based proteomics, which demonstrated to be an unrivalled tool for the analyses of protein post-translational modifications associated with chromatin modifications. In particular, high-resolution mass spectrometry has been recently used for systematic quantification of chromatin modifications. Data generated by this approach are central in the search for new therapies for various forms of cancer and will help in attempts to decipher antitumor drug resistance. To appreciate the contribution of mass spectrometry-based proteomics to biomarkers discovery and to our understanding of mechanisms behind the initiation and progression of various forms of cancer, a number of recent investigations are discussed. These investigations also include results provided by two-dimensional gel electrophoresis combined with mass spectrometry. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessFeature PaperReview

Interstitial Cells of Cajal—Origin, Distribution and Relationship with Gastrointestinal Tumors

and

Medicina 2023, 59(1), 63; https://doi.org/10.3390/medicina59010063 - 28 Dec 2022

Viewed by 2535

Abstract

The interstitial cells of Cajal (ICC) represent a particular network formed by some peculiar cells that were first described by the great neuroanatomist, S. Ramon y Cajal. Nowadays, the ICC have become a fascinating topic for scientists, arousing their curiosity; as a result, there is a vast number of published articles related to the ICC. Today, everybody widely accepts that the ICC represent the pacemaker of the gastrointestinal tract and are highly probable to be the origin cells for gastrointestinal tumors (GISTs). Recently, Cajal-like cells (ICLC) were described, which are found in different organs but with an as yet unknown physiological role that needs further study. New information regarding intestinal development indicates that the ICC (fibroblast-like and muscle-like) and intestinal muscle cells have the same common embryonic cells, thereby presenting the same cellular ultrastructure. Nowadays, there is a vast quantity of information that proves the connection of the ICC and GISTs. Both of them are known to present c-kit expression and the same ultrastructural cell features, which includes minimal myoid differentiation that is noticed in GISTs, therefore, supporting the hypothesis that GISTs are ICC-related tumors. In this review, we have tried to highlight the origin and distribution of Cajal interstitial cells based on their ultrastructural features as well as their relationship with gastrointestinal stromal tumors. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Other

Jump to: Editorial, Research, Review

Open AccessCase Report

The Philadelphia Chromosome, from Negative to Positive: A Case Report of Relapsed Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation

Elena-Cristina Marinescu

and

Medicina 2023, 59(4), 671; https://doi.org/10.3390/medicina59040671 - 28 Mar 2023

Viewed by 516

Abstract

Relapsed acute lymphoblastic leukemia (ALL) represents a continuous challenge for the clinician. Despite recent advances in treatment, the risk of relapse remains significant. The clinical, biological, cytogenetic, and molecular characteristics may be different at the time of relapse. Current comprehensive genome sequencing studies suggest that most relapsed patients, especially those with late relapses, acquire new genetic abnormalities, usually within a minor clone that emerges after ALL diagnosis. We report the case of a 23-year-old young woman diagnosed with Philadelphia chromosome-negative B cell acute lymphoblastic leukemia. The patient underwent allogeneic stem cell transplantation (allo-HSCT) after complete remission. Despite having favorable prognostic factors at diagnosis, the disease relapsed early after allo-HSCT. The cytogenetic and molecular exams at relapse were positive for the Philadelphia chromosome, respectively for the Bcr-Abl transcript. What exactly led to the recurrence of this disease in a more aggressive cytogenetic and molecular form, although there were no predictive elements at diagnosis? Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Open AccessCase Report

The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report

Veronica Aran

Vinicius Mansur Zogbi

Renan Lyra Miranda

Felipe Andreiuolo

Nathalie Henriques Silva Canedo

Carolina Victor Nazaré

Paulo Niemeyer Filho

and

Vivaldo Moura Neto

Medicina 2023, 59(3), 459; https://doi.org/10.3390/medicina59030459 - 25 Feb 2023

Viewed by 524

Abstract

Different cancers have multiple genetic mutations, which vary depending on the affected tumour tissue. Small biopsies may not always represent all the genetic landscape of the tumour. To improve the chances of identifying mutations at different disease stages (early, during the disease course, and refractory stage), liquid biopsies offer an advantage to traditional tissue biopsy. In addition, it is possible to detect mutations related to metastatic events depending on the cancer types analysed as will be discussed in this case report, which describes a patient with brain metastasis and lung cancer that harboured K-RAS mutations both in the brain tumour and in the ctDNA present in the bloodstream. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies)

► Show Figures

Figure 1

Show export options Show export options

Select all

Export citation of selected articles as:

Displaying articles 1-12

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: PARATHYROID CANCER – A RARE FINDING DURING PARATHYROIDECTOMY IN HIGH VOLUME SURGERY CENTRE
Authors: Radu Petru; Garofil Dragos; Anca Tigora; M. Zurzu; V.Paic; M. Bratucu,; Mircea Litescu; Virgil Prunoiu; V. Georgescu; F.Popa; V Strambu
Affiliation: General Surgery Clinic, Clinical Nephrology Hospital “Dr. Carol Davila”, Bucharest, Romania
Abstract: Parathyroid cancer is a very rare endocrine tumor, especially in patients with secondary hyperparathyroidism due to end stage renal disease failure. This pathology is difficult to diagnose preoperatively because it has non-specific clinical manifestations and paraclinical aspects. Our study of the literature identified 34 reported cases of parathyroid carcinoma over the last 40 years. From January 2012 to November 2022, 650 patients with secondary hyperparathyroidism undergoing dialysis were treated at our academic Department of General Surgery and only 2 cases of parathyroid carcinoma were diagnosed on histopathological examination. Surgical approach is the only valid treatment to remove the malignant tissue, to control hypercalcemia and thus improve the patient’s prognosis.

Title: Emergency colorectal oncological surgery – influences on the surgical strategy and postoperative morbidity and mortality
Authors: Valentin Titus Grigorean
Affiliation: “Bagdasar-Arseni” Clinical Emergency Hospital, Bucharest, Romania; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Abstract: /

Title: Epidemiology, diagnosis and treatment of sacral tumors
Authors: Valentin Titus Grigorean; Oana Ilona David
Affiliation: Bagdasar-Arseni” Clinical Emergency Hospital, Bucharest, Romania
Abstract: /

Title: Rhabdomyosarcoma of the inguinal canal mimicking an inguinal hernia – Review of the literature and presentation of a particular case
Authors: Ionuţ Simion Coman
Affiliation: “Bagdasar-Arseni” Clinical Emergency Hospital, Bucharest, Romania; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Abstract: /

Journal Menu

Journal Browser

Special Issue "Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (12 papers)

Editorial

Research

Review

Other

Planned Papers

Further Information

Guidelines

MDPI Initiatives

Follow MDPI